Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$12.57M+28.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Patrick Mercer
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 93
- Beta
- 0.63
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.58
Financials
Revenue
$12.57M+28.4%Net Income
$-1.27MEBITDA
$-667.0KFree Cash Flow
$275.0KEPS (diluted)
$-0.07Shares Outstanding (diluted)
17.38M+71.5%Operating Expenses
$5.33MCash & Debt
$4.68MReturn of Capital
$0.00Revenue by Segment (annual)
$52.67MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $52.67M | $-4.44M | $-0.26 |
| 2024 | $48.67M | $-8.91M | $-0.54 |
| 2023 | $51.87M | $-9.57M | $-0.59 |
| 2022 | $56.97M | $-7.55M | $-0.47 |
| 2021 | $53.90M | $-5.22M | $-0.34 |
| 2020 | $36.35M | $-6.33M | $-0.46 |
| 2019 | $43.45M | $-8.81M | $-0.64 |
| 2018 | $42.60M | $-12.81M | $-1.05 |
| 2017 | $41.59M | $-12.87M | $-1.11 |
| 2016 | $46.16M | $-11.71M | $-1.15 |
| 2015 | $41.76M | $474.0K | $0.05 |
| 2014 | $42.81M | $10.04M | $1.01 |
| 2013 | $38.27M | $2.23M | $0.24 |
| 2012 | $33.86M | $1.44M | $0.16 |
Valuation
IRIXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.75%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·1d ago·Neutral
Iridex Completes Relocation of Manufacturing Facility to San Jose, California Company Expects to Realize Approximately $600,000 in Annualized Cost Savings Company Expects to Realize Approximately $600,000 in Annualized Cost Savings
View source ↗ - Newszacks.com·41d ago·Negative
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15% IRIX's Q2 loss per share widens year over year and revenues decline as Middle East disruptions and reduced sell-through in China weigh on retina sales, offsetting continued growth in the Cyclo G6 product family.
View source ↗ - Newsseekingalpha.com·48d ago·Positive
IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript IRIDEX Corporation (IRIX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·48d ago·Neutral
Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026.
View source ↗
Earnings
Tue, Nov 17(in 6 weeks)
Consensus estimate $-0.04 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 18$-0.07 vs $-0.01miss
- Tue, May 19$-0.03 vs $-0.07beat
- Thu, Mar 26$-0.01 vs $-0.02beat
- Tue, Nov 11$-0.09 vs $-0.02miss
- Tue, Aug 12$-0.06 vs $-0.09beat
- Tue, May 13$-0.10 vs $-0.10beat
Estimates and results for IRIX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IRIX officers and directors.
- Bought
- $193k
- Sold
- —
84 trades
0 trades
- Dizon Romeo Rbought
- Dizon Romeo Rbought
- Dizon Romeo Rbought
- Dizon Romeo Rbought
- Dizon Romeo Rbought
- Dizon Romeo Rbought
- Dizon Romeo Rbought
- Dizon Romeo Rbought
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IRIX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.